The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Adenosine and cAMP are potent inhibitors of the NF‐κB pathway downstream of immunoreceptors
Open accessAbstract
Anergic B lymphocytes exert compromised signal transduction towards the activation of NF‐κB in response to B cell antigen receptor (BCR) triggering, whereas activation of the ERK pathway appears normal. How this differential down‐regulation of the NF‐κB pathway is regulated remains still elusive. Here, we demonstrate that stimuli known to enhance 3′,5′‐cyclic adenosine monophosphate (cAMP) are capable of selectively suppressing the activation both of NF‐κB downstream of the BCR and Toll‐like receptor 4 in splenic B lymphocytes and of the high‐affinity receptor for IgE in BM‐derived mast cells. This suppression is accomplished by blocking phosphorylation and subsequent degradation of the inhibitor of NF‐κB. A cAMP‐dependent protein kinase (PKA) inhibitor reverses this suppressive effect, indicating that PKA is a downstream effector of cAMP in this process. Importantly, not only drugs that artificially elevate intracellular cAMP levels, but also the nucleoside adenosine, which is known to be a mediator of cellular distress, inhibit the NF‐κB pathway. This suggests that adenosine‐mediated signals represent an important step in the molecular decision process controlling inflammation versus anergic immune responses. See accompanying Commentary: http://dx.doi.org/10.1002/eji.200425738
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
CARMA1, BCL-10 and MALT1 in lymphocyte development and activation
Thome, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1352 · Cited by 391
Hashimoto, A., Okada, H., Jiang, A., Kurosaki, M., Greenberg, S., Clark, E. A., & Kurosaki, T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.7.1287 · Cited by 199
Cited by
Bours, M. J. L., Swennen, E. L. R., Di Virgilio, F., Cronstein, B. N., & Dagnelie, P. C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.013 · Cited by 1,030
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading
Pols, T. W. H., Nomura, M., Harach, T., Lo Sasso, G., Oosterveer, M. H., Thomas, C., Rizzo, G., Gioiello, A., Adorini, L., Pellicciari, R., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.006 · Cited by 610
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Rahimifard, M., Maqbool, F., Moeini-Nodeh, S., Niaz, K., Abdollahi, M., Braidy, N., Nabavi, S. M., & Nabavi, S. F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.004 · Cited by 481
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target
Sojka, D. K., Huang, Y., & Fowell, D. J. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02813.x · Cited by 393
CD73: a potent suppressor of antitumor immune responses
Beavis, P. A., Stagg, J., Darcy, P. K., & Smyth, M. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.009 · Cited by 355
Yoshikawa, H., Kurokawa, M., Ozaki, N., Nara, K., Atou, K., Takada, E., Kamochi, H., & Suzuki, N. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03169.x · Cited by 289
A Cross-Sectional Study of Cannabidiol Users
Corroon, J., & Phillips, J. A. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0006 · Cited by 289
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Li, X.-Y., Moesta, A. K., Xiao, C., Nakamura, K., Casey, M., Zhang, H., Madore, J., Lepletier, A., Aguilera, A. R., Sundarrajan, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0541 · Cited by 264
Metadata
- Authors
- Minguet, S., Huber, M., Rosenkranz, L., Schamel, W. W. A., Reth, M., & Brummer, T.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2004-12-16
- Volume
- 35
- Issue
- 1
- Pages
- 31-41
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2003641968
- Cited by
- 197
- References
- 3
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.